FLT4 anticorps

N° du produit ABIN1589828

Cet anticorps anti-FLT4 est un anticorps Lapin Polyclonal détectant FLT4 dans WB, ELISA, IP et IHC (af). Adapté pour Humain. Ce Primary Antibody a été cité dans 1 publication.

Aperçu rapide pour FLT4 anticorps (ABIN1589828)

Antigène: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp FLT4 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunoprecipitation (IP), Immunohistochemistry (Acetone-fixed) (IHC (af))

Détail du produit anti-FLT4 anticorps

Fonction: VEGFR-3/FLT-4 antibody

Specificité: Recombinant human sFLT-4 (D1-7)

Attributs du produit: Chromosomal location: 5q35.3
Produced from sera of rabbits immunised with highly pure recombinant human soluble VEGFR-3/FLT-4 (D1-D7).

Purification: Anti-human VEGFR-3/FLT-4 was purified by antigen-affinity chromatography with immobilised soluble VEGFR-3/FLT-4.

Immunogène: Recombinant human sFLT-4 (D1-7) (ABIN1589554 and ABIN1589553)

Isotype: IgG

Information d'application

Indications d'application: Western Blot: Use 1-5 μg/mL

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.

Buffer: PBS

Conseil sur la manipulation: Centrifuge vial prior to opening.

Stock: 4 °C,-20 °C

Stockage commentaire: The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.

Date de péremption: 24 months

Références pour anticorps anti-FLT4 (ABIN1589828)

Liu, Li, Zhang, Rao, Liang, Liu: "The defect of both angiogenesis and lymphangiogenesis is involved in preeclampsia." dans: Placenta, Vol. 36, Issue 3, pp. 279-86, (2015) (PubMed).

Détails sur FLT4

Antigène: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Autre désignation: VEGFR-3/FLT-4

Sujet: Vascular endothelial growth factor receptor-3, FLT4, PCL, LMPH1A, VEGFR3, fms-related tyrosine kinase 4,Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (FIT1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1-D7), a single transmembrane (TM) helix and cytoplasmic region with a tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelia cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system.

ID gène: 2324

NCBI Accession: NM_002020, NP_002011

UniProt: P35916

Pathways: Signalisation RTK, Signaling Events mediated by VEGFR1 and VEGFR2, VEGF Signaling